Y412 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׸»¶ó¸®¾ÆÁ¦ ¹× ±âŸ Ç÷¾×³» ¿øÃæ·ù¿¡ ÀÛ¿ëÇÏ´Â ¾à¹° | Antimalarials and drugs acting on other blood protozoa causing adverse effects in therapeutic use |
 |
Y413 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç׿øÃæÁ¦ | Other antiprotozoal drugs causing adverse effects in therapeutic use |
 |
Y414 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÃæÁ¦ | Anthelminthics causing adverse effects in therapeutic use |
 |
Y415 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×¹ÙÀÌ·¯½ºÁ¦ | Antiviral drugs causing adverse effects in therapeutic use |
 |
Y418 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¸í½ÃµÈ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ | Other specified systemic anti-infectives and antiparasitics causing adverse effects in therapeutic use |
 |
Y418 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÇÏÀ̵å·Ï½ÃÄû³ë¸° À¯µµÃ¼ | Hydroxyquinoline derivatives causing adverse effects in therapeutic use |
 |
Y419 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Àü½Å Ç×°¨¿°Á¦ ¹× Ç×±â»ýÃæÁ¦ | Systemic anti-infective and antiparasitic, unspecified causing adverse effects in therapeutic use |
 |
Y42 | Ä¡·á½Ã ºÎÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È£¸£¸ó ¹× ±×µéÀÇ ÇÕ¼º ´ë¿ëǰ ¹× ´ëÇ×Á¦(±æÇ×Á¦) | Hormones and their synthetic substitutes and antagonists,NEC causing adverse effects in therapeutic use |
 |
Y420 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±Û·çÄÚÄÝÆ¼ÄÚÀÌµå ¹× ÇÕ¼º´ëÄ¡¹° | Glucocorticoids and synthetic analogues causing adverse effects in therapeutic use |
 |
Y421 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °©»ó¼± È£¸£¸ó ¹× ´ëÄ¡¹° | Thyroid hormones and substitutes causing adverse effects in therapeutic use |
 |
Y422 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°©»ó¼±Á¦ | Antithyroid drugs causing adverse effects in therapeutic use |
 |
Y423 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Àν¶¸° ¹× °æ±¸ÀúÇ÷´ç[Ç×´ç´¢º´]Á¦ | Insulin and oral hypoglycemic [antidiabetic] drugs causing adverse effects in therapeutic use |
 |
Y424 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °æ±¸ÇÇÀÓÁ¦ | Oral contraceptives causing adverse effects in therapeutic use |
 |
Y424 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Ù¼ººÐ ¹× ´ÜÀϼººÐ Á¦Á¦ | Multiple-and single-ingredient preparations causing adverse effects in therapeutic use |
 |
Y425 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð | Other estrogens and progestogens causing adverse effects in therapeutic use |
 |
Y425 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â È¥ÇÕ¹° ¹× ´ëÄ¡¹° | Mixtures and substitutes causing adverse effects in therapeutic use |
 |
Y426 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×°í³ªµµÆ®·ÎÇÉÁ¦, Ç׿¡½ºÆ®·ÎÁ¨Á¦, Ç׾ȵå·ÎÁ¨Á¦ | Antigonadotrophins, antiestrogens, antiandrogens, NEC causing adverse effects in therapeutic use |
 |
Y426 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ÿ¸ñ½ÃÆæ | Tamoxifen causing adverse effects in therapeutic use |
 |
Y427 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Èµå·ÎÁ¨ ¹× ÇÕ¼º´ë»ç µ¿Á¾Ã¼ | Androgens and anabolic congeners causing adverse effects in therapeutic use |
 |
Y428 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ¹× ÇÕ¼º ´ëÄ¡¹° | Other and unspecified hormones and their synthetic substitutes causing adverse effects in therapeutic use |
 |